Sunscreen Drug Products for Over-the-Counter Human Use; Correction, 16220-16222 [2019-07712]
Download as PDF
<![CDATA[
16220
Federal Register / Vol. 84, No. 75 / Thursday, April 18, 2019 / Proposed Rules
VOR/DME
Fix
VORTAC
T–295 POORK, VA to Bangor,
POORK, VA
KREGG, VA
HOUKY, VA
TAPPA, VA
COLIN, VA
SHLBK, MD
LOUIE, MD
GRACO, MD
VYSOR, MD
BAABS, MD
Lancaster, PA (LRP)
DUMMER, PA
HAILS, PA
SNOWY, PA
KRAZE, PA
LYTEL, PA
Wilkes-Barre, PA (LVZ)
LAAYK, PA
KERRI, NY
PRNCE, NY
SAGES, NY
TALCO, NY
WIGAN, NY
BOWAN, NY
MOBBS, MA
SASHA, MA
MOLDS, MA
WHATE, MA
WARIC, MA
Keene, NH (EEN)
TAPSE, NH
Concord, NH (CON)
SATAN, ME
Kennebunk, ME (ENE)
BRNNS, ME
RAZZR, ME
Bangor, ME (BGR)
*
*
*
*
*
Issued in Washington, DC, on April 10,
2019.
M. Colby Abbott,
Acting Manager, Airspace Policy Group.
[FR Doc. 2019–07597 Filed 4–17–19; 8:45 am]
BILLING CODE 4910–13–P
(Lat. 42°10′41.81″ N, long. 074°57′24.99″ W)
(Lat. 42°26′26.98″ N, long. 074°25′48.33″ W)
(Lat. 42°44′50.21″ N, long. 073°48′11.47″ W)
ME (BGR) [Amended]
(Lat.
WP
(Lat.
WP
(Lat.
Fix
(Lat.
Fix
(Lat.
WP
(Lat.
Fix
(Lat.
Fix
(Lat.
WP
(Lat.
WP
(Lat.
VORTAC
(Lat.
Fix
(Lat.
Fix
(Lat.
Fix
(Lat.
Fix
(Lat.
Fix
(Lat.
VORTAC
(Lat.
Fix
(Lat.
Fix
(Lat.
Fix
(Lat.
Fix
(Lat.
Fix
(Lat.
Fix
(Lat.
Fix
(Lat.
Fix
(Lat.
Fix
(Lat.
Fix
(Lat.
Fix
(Lat.
Fix
(Lat.
VORTAC
(Lat.
Fix
(Lat.
VOR/DME
(Lat.
Fix
(Lat.
VOR/DME
(Lat.
Fix
(Lat.
Fix
(Lat.
VORTAC
(Lat.
36°34′11.34″
36°51′07.95″
37°19′55.98″
37°58′12.66″
38°05′59.23″
38°20′16.21″
38°36′44.33″
38°56′29.81″
39°02′03.86″
39°19′51.39″
40°07′11.91″
40°28′10.68″
40°34′13.43″
40°45′05.77″
40°50′13.14″
40°55′48.79″
41°16′22.10″
41°28′32.64″
41°50′37.49″
41°58′24.75″
42°02′46.33″
42°03′45.97″
42°05′06.33″
42°06′23.14″
42°07′30.84″
42°07′58.70″
42°12′30.91″
42°26′10.03″
42°37′42.00″
42°47′39.40″
43°04′16.55″
43°13′11.23″
43°23′09.13″
43°25′32.42″
43°54′08.64″
44°13′16.51″
44°50′30.46″
N,
N,
N,
N,
N,
N,
N,
N,
N,
N,
N,
N,
N,
N,
N,
N,
N,
N,
N,
N,
N,
N,
N,
N,
N,
N,
N,
N,
N,
N,
N,
N,
N,
N,
N,
N,
N,
long.
long.
long.
long.
long.
long.
long.
long.
long.
long.
long.
long.
long.
long.
long.
long.
long.
long.
long.
long.
long.
long.
long.
long.
long.
long.
long.
long.
long.
long.
long.
long.
long.
long.
long.
long.
long.
077°35′21.39″
077°25′17.57″
077°07′57.63″
076°50′40.62″
076°39′50.85″
076°26′10.51″
076°18′04.37″
076°11′59.22″
076°14′59.88″
076°24′40.87″
076°17′28.66″
076°06′40.18″
076°03′31.77″
075°57′51.63″
075°55′10.83″
075°52′14.42″
075°41′22.07″
075°28′57.31″
074°44′14.93″
074°28′12.25″
074°19′10.33″
074°06′27.85″
073°48′53.89″
073°31′28.95″
073°15′36.59″
073°08′55.39″
073°03′13.39″
072°45′41.96″
072°30′37.72″
072°17′30.40″
071°49′38.92″
071°34′31.63″
070°48′11.07″
070°36′48.69″
069°56′42.81″
069°35′12.25″
068°52′26.27″
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Part 201
[Docket No. FDA–1978–N–0018 (formerly
Docket No. FDA–1978–N–0038)]
RIN 0910–AF43
Sunscreen Drug Products for Over-theCounter Human Use; Correction
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Proposed rule; correction.
The Food and Drug
Administration (FDA) is correcting a
proposed rule relating to the regulation
of over-the-counter (OTC) sunscreen
monograph products that appeared in
the Federal Register of February 26,
2019. The document was published
jbell on DSK30RV082PROD with PROPOSALS
SUMMARY:
VerDate Sep<11>2014
16:59 Apr 17, 2019
Jkt 247001
PO 00000
Frm 00004
Fmt 4702
Sfmt 4725
W)
W)
W)
W)
W)
W)
W)
W)
W)
W)
W)
W)
W)
W)
W)
W)
W)
W)
W)
W)
W)
W)
W)
W)
W)
W)
W)
W)
W)
W)
W)
W)
W)
W)
W)
W)
W)
with formulas that were illegible. These
corrections are being made to improve
the accuracy of the proposed rule.
Submit either electronic or
written comments on the proposed rule
by June 27, 2019.
DATES:
FOR FURTHER INFORMATION CONTACT:
Kristen Hardin, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, Rm. 5443,
Silver Spring, MD 20993, 240–402–
4246.
In the
Federal Register of February 26, 2019
(84 FR 6204), in FR Doc. 2019–03019,
on pages 6267 through 6270, the
following corrections are made:
1. On page 6267, in the first column,
the formula under § 201.327(i)(2)(ii)(B)
is corrected to read:
SUPPLEMENTARY INFORMATION:
BILLING CODE 4164–01–P
E:\FR\FM\18APP1.SGM
18APP1
EP18AP19.004</GPH>
Delancey, NY (DNY)
OAKIL, NY
Albany, NY (ALB)
Federal Register / Vol. 84, No. 75 / Thursday, April 18, 2019 / Proposed Rules
2. On page 6268, in the second
column, the formula under
§ 201.327(i)(3)(ii)(C)(2) is corrected to
read:
3. On page 6268, in the second
column, the formulas under
§ 201.327(i)(3)(ii)(D)(2)(i) are corrected
to read:
16221
4. On page 6269, in the third column,
the formula under § 201.327(i)(7)(i) is
corrected to read:
5. On page 6269, in the third column,
the formulas under § 201.327(i)(7)(ii) are
corrected to read:
EP18AP19.008</GPH>
EP18AP19.009</GPH>
6. On page 6270, in the second
column, the formula under
§ 201.327(j)(4)(ii) is corrected to read:
EP18AP19.007</GPH>
EP18AP19.006</GPH>
VerDate Sep<11>2014
16:59 Apr 17, 2019
Jkt 247001
PO 00000
Frm 00005
Fmt 4702
Sfmt 4702
E:\FR\FM\18APP1.SGM
18APP1
EP18AP19.005</GPH>
jbell on DSK30RV082PROD with PROPOSALS
7. On page 6270, in the third column,
the formulas under § 201.327(j)(5)(i) are
corrected to read:
16222
Federal Register / Vol. 84, No. 75 / Thursday, April 18, 2019 / Proposed Rules
8. On page 6270, in the third column,
the formula under § 201.327(j)(7) is
corrected to read:
9. On page 6270, in the third column,
the formula under § 201.327(j)(8) is
corrected to read:
BILLING CODE 4164–01–C
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–1978–N–0018 (formerly
Docket No. FDA–1978–N–0038)]
FDA is extending the comment
period on the proposed rule published
February 26, 2019 (84 FR 6204). Submit
either electronic or written comments
by June 27, 2019.
RIN 0910–AF43
ADDRESSES:
DATES:
21 CFR Parts 201, 310, 347, and 352
Sunscreen Drug Products for Over-theCounter Human Use; Extension of
Comment Period
AGENCY:
Food and Drug Administration,
jbell on DSK30RV082PROD with PROPOSALS
HHS.
Proposed rule; extension of
comment period.
ACTION:
The Food and Drug
Administration (FDA or the Agency) is
extending the comment period for the
proposed rule that appeared in the
Federal Register of February 26, 2019.
SUMMARY:
VerDate Sep<11>2014
16:59 Apr 17, 2019
Jkt 247001
You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before June 27, 2019.
The https://www.regulations.gov
electronic filing system will accept
comments until 11:59 p.m. Eastern Time
at the end of June 27, 2019. Comments
received by mail/hand delivery/courier
(for written/paper submissions) will be
considered timely if they are
postmarked or the delivery service
acceptance receipt is on or before that
date.
PO 00000
Frm 00006
Fmt 4702
Sfmt 4702
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
E:\FR\FM\18APP1.SGM
18APP1
EP18AP19.012</GPH>
[FR Doc. 2019–07712 Filed 4–17–19; 8:45 am]
Electronic Submissions
EP18AP19.011</GPH>
Dated: April 12, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
In the proposed rule, FDA requested
comments on its proposals relating to
the regulation of over-the-counter (OTC)
sunscreen monograph products. These
proposals described the conditions
under which the Agency proposes that
OTC sunscreen monograph products are
generally recognized as safe and
effective and not misbranded. The
Agency is taking this action in response
to a request for an extension to allow
interested persons additional time to
submit comments.
EP18AP19.010</GPH>
Elsewhere in this issue of the Federal
Register, FDA is extending the comment
period on the proposed rule.
]]>Agencies
[Federal Register Volume 84, Number 75 (Thursday, April 18, 2019)]
[Proposed Rules]
[Pages 16220-16222]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-07712]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 201
[Docket No. FDA-1978-N-0018 (formerly Docket No. FDA-1978-N-0038)]
RIN 0910-AF43
Sunscreen Drug Products for Over-the-Counter Human Use;
Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Proposed rule; correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is correcting a
proposed rule relating to the regulation of over-the-counter (OTC)
sunscreen monograph products that appeared in the Federal Register of
February 26, 2019. The document was published with formulas that were
illegible. These corrections are being made to improve the accuracy of
the proposed rule.
DATES: Submit either electronic or written comments on the proposed
rule by June 27, 2019.
FOR FURTHER INFORMATION CONTACT: Kristen Hardin, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, Rm. 5443, Silver Spring, MD 20993, 240-402-
4246.
SUPPLEMENTARY INFORMATION: In the Federal Register of February 26, 2019
(84 FR 6204), in FR Doc. 2019-03019, on pages 6267 through 6270, the
following corrections are made:
1. On page 6267, in the first column, the formula under Sec.
201.327(i)(2)(ii)(B) is corrected to read:
BILLING CODE 4164-01-P
[GRAPHIC] [TIFF OMITTED] TP18AP19.004
[[Page 16221]]
2. On page 6268, in the second column, the formula under Sec.
201.327(i)(3)(ii)(C)(2) is corrected to read:
[GRAPHIC] [TIFF OMITTED] TP18AP19.005
3. On page 6268, in the second column, the formulas under Sec.
201.327(i)(3)(ii)(D)(2)(i) are corrected to read:
[GRAPHIC] [TIFF OMITTED] TP18AP19.006
4. On page 6269, in the third column, the formula under Sec.
201.327(i)(7)(i) is corrected to read:
[GRAPHIC] [TIFF OMITTED] TP18AP19.007
5. On page 6269, in the third column, the formulas under Sec.
201.327(i)(7)(ii) are corrected to read:
[GRAPHIC] [TIFF OMITTED] TP18AP19.008
6. On page 6270, in the second column, the formula under Sec.
201.327(j)(4)(ii) is corrected to read:
[GRAPHIC] [TIFF OMITTED] TP18AP19.009
7. On page 6270, in the third column, the formulas under Sec.
201.327(j)(5)(i) are corrected to read:
[[Page 16222]]
[GRAPHIC] [TIFF OMITTED] TP18AP19.010
8. On page 6270, in the third column, the formula under Sec.
201.327(j)(7) is corrected to read:
[GRAPHIC] [TIFF OMITTED] TP18AP19.011
9. On page 6270, in the third column, the formula under Sec.
201.327(j)(8) is corrected to read:
[GRAPHIC] [TIFF OMITTED] TP18AP19.012
Elsewhere in this issue of the Federal Register, FDA is extending
the comment period on the proposed rule.
Dated: April 12, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019-07712 Filed 4-17-19; 8:45 am]
BILLING CODE 4164-01-C
